Amgen Sues Pfizer Over US Pegfilgrastim Biosimilar
Meanwhile aBLA For Pegfilgrastim Is Being Reviewed By FDA
Executive Summary
Amgen has filed a US patent-infringement lawsuit against Pfizer’s Hospira over its biosimilar pegfilgrastim rival to Neulasta.